• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Akeso

FDA
Pharma

FDA slams China-heavy data in Summit’s ivonescimab CRL

FDA reviewers also flagged concerns over the geographic makeup of Summit’s HARMONi trial, noting that 93% of the PFS events occurred in China.
Angus Liu Nov 17, 2026 4:48pm
FDA stop sign

FDA rejects Summit’s PD-1xVEGF ivonescimab in NSCLC

Nov 15, 2026 7:50am
Asia

Enhertu successor, ESMO, Gilead—Fierce Pharma Asia

Oct 30, 2026 8:45am
Xia

Akeso CEO looks for more ivonescimab combos after AZ deal

Oct 25, 2026 11:30am
Asia

US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia

Sep 18, 2026 10:20am
fight

Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC

Sep 13, 2026 8:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings